Sanofi Launches Local Production of Soliqua® in Beijing, Reinforcing Commitment to China's Healthcare Innovation

Boosting Local Production Layout, Entering a New Era of Healthcare Together

BeijingJune 9, 2023PR Newswire -- Yesterday, Sanofi, a global leading innovative pharmaceuticals and healthcare company, held a grand event at its Beijing production base for the product Saiyining.^®Launch Ceremony of the Real Estate Project: Innovative Compound Preparation for Diabetes, Soliqua, Officially Launched^® Local production in China. During the collective visit of Sanofi's Global Executive Committee members to China, Brendan O'Callaghan, Sanofi’s Global Executive Vice President and Head of Manufacturing and Supply, Olivier Charmeil (夏立维), Sanofi’s Executive Vice President and Head of General Medicines Global Business Unit, and other Executive Committee representatives attended the ceremony. Additionally, government representatives such as Liu Li, Deputy Director of the Beijing Economic-Technological Development Area Management Committee, and Wang Houting, Deputy Director of the Beijing Municipal Drug Administration, were present at the event to join Sanofi in witnessing this significant moment of deepening local presence.

Representatives of the Sanofi Global Executive Committee, relevant representatives of Sanofi's Manufacturing and Supply Division in China, together with representatives from Beijing Economic-Technological Development Zone (BDA) and the Drug Administration, jointly announced the launch of the Lantus® Localization Project.

Global Executive Vice President of Sanofi, Head of Manufacturing and Supply DivisionBrendan O'CallaghanSpeech on site："From1995Since its establishment in [Year], the Beijing production base has been dedicated to meeting the growing health needs of Chinese patients in areas such as diabetes, cardiovascular diseases, oncology, and wellness. This time, Soliqua^®The official launch of local production marks another milestone in our long-term strategic layout in China, covering manufacturing sites in Beijing, Hangzhou, and Shenzhen.China Plays an Important Role in Sanofi's Global Strategy, the continuously expanding localized production further demonstrates our unwavering confidence and commitment to the Chinese market. Here, the strong workforce we have and the support from local partners will drive our continuous innovation in production technology and digitalization. In the future, Sanofi will continue to invest in R&D, advanced manufacturing and supply capabilities, as well as talent development, helping to accelerate the realization of our ambition to bring scientific miracles to the Chinese people as quickly as possible. Moreover, we actively implement environmental protection measures in our operations to achieve carbon reduction goals. We look forward to working with multiple partners to continue making positive contributions to the development of China's healthcare industry."

Brendan O'Callaghan, Global Executive Vice President of Sanofi and Head of the Manufacturing and Supply Division, Delivers a Speech on Site

"This visit to the Beijing production base left a deep impression on me in two aspects: one is ‘quality', which refers not only to the high standards in the production process but also to the high-quality training of talent; the other is ‘environmental protection', through the practice of green production and supply chain, we are actively contributing to sustainable development." Shaliv (Executive Vice President of Sanofi and Head of the Global General Medicines Division)Olivier Charmeil) shared in the opening remarks，"China is Sanofi's second-largest market globally, holding extraordinary strategic significance. As a 'localized multinational pharmaceutical company' with years of deep involvement, we profoundly feel the innovative development in China and will spare no effort to enhance our capabilities.2020To2025Introduce at least25An innovative product that delivers on its commitment to China with higher-quality offerings, marking a new phase in its 'miraculous' journey in China under continuous efforts to deepen its local presence."

Olivier Charmeil, Executive Vice President of Sanofi and Head of the Global General Medicines Division, delivers a speech on site.

Boosting Local Insulin Production, Deepening Commitment to Meet the Health Needs of Chinese Patients

This launch ceremony marks Sanofi^®Local production has officially landed at the Beijing production base. The project involves a total investment of nearly 500 million RMB, with plans to build a new aseptic filling production line and upgrade and renovate the existing assembly production line. This will continuously expand the manufacturing capacity of insulin products, further increase local production capacity in China, enhance the innovation and accessibility of high-quality products, and better meet the treatment needs of Chinese diabetes patients. Local product assembly is expected to officially begin in the first quarter of 2024.

Diabetes Innovation Drug: Soliqua^®[Insulin Glargine and Lixisenatide Injection (I)/(II)] was officially approved for marketing in China earlier this year. It took only four months to complete the entire production and market launch process, and the first prescriptions have recently been issued in many parts of China. This also means that patients with diabetes in China now have a new treatment option that balances blood sugar control, reduces the risk of hypoglycemia, and does not lead to weight gain.

Following this year4Sanofi CEO to Visit China Again Next MonthHan Paul (Paul Hudson) Shared the feelings of this visit to China，"We see that the Chinese market is still full of vitality, which makes us more optimistic about the long-term development prospects in this land. Sanofi^®The official launch of local production in China is another significant step by Sanofi to strengthen its investment layout in the country. While contributing to Beijing's development into a world-class biopharmaceutical innovation hub, Sanofi, with the mission of "pursuing scientific miracles and revitalizing the brilliance of life," is committed to bringing more innovative and high-quality healthcare solutions to the Chinese market for the benefit of more patients."

Wang Shi, President of Sanofi Greater China, said："Rooted in China40For many years, Sanofi has been committed to continuously exploring treatment solutions that are more suitable for Chinese patients. This move to strengthen the local production layout of insulin demonstrates our unwavering confidence in the Chinese market. With the strong support of favorable local policies in Beijing, we will continue to deepen our local investment and collaborate to build a new pattern for the development of China's healthcare industry."

The Sanofi Beijing production base, which has received strong support from the local government since its establishment in the Beijing Economic-Technological Development Area, is now undergoing capital increase and commencing operations. The continuously open and innovation-friendly business environment has provided a solid foundation for Sanofi’s development in China, further strengthening the company’s confidence and determination to deepen its local practices. Currently, the Beijing production base has become Sanofi's largest insulin injection production site in the Asia-Pacific region, with its innovative achievements benefiting markets in China and even globally. This launch ceremony undoubtedly marks another successful localized strategic cooperation between Sanofi and the Beijing government. In the future, both parties will continue to deepen their collaboration, jointly promoting the vigorous development of China's health and hygiene initiatives.